117 related articles for article (PubMed ID: 2181071)
1. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
Hank JA; Sosman JA; Kohler PC; Bechhofer R; Storer B; Sondel PM
J Biol Response Mod; 1990 Feb; 9(1):5-14. PubMed ID: 2181071
[TBL] [Abstract][Full Text] [Related]
2. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
3. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.
Hank JA; Kohler PC; Weil-Hillman G; Rosenthal N; Moore KH; Storer B; Minkoff D; Bradshaw J; Bechhofer R; Sondel PM
Cancer Res; 1988 Apr; 48(7):1965-71. PubMed ID: 3258180
[TBL] [Abstract][Full Text] [Related]
4. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.
Vose BM; Bonnard GD
J Immunol; 1983 Feb; 130(2):687-93. PubMed ID: 6600251
[TBL] [Abstract][Full Text] [Related]
5. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
Rosenthal NS; Hank JA; Kohler PC; Minkoff DZ; Moore KH; Bechhofer R; Hong R; Storer B; Sondel PM
J Biol Response Mod; 1988 Apr; 7(2):123-39. PubMed ID: 3258904
[TBL] [Abstract][Full Text] [Related]
6. Functional properties of the 50 kd protein associated with the E-receptor on human T lymphocytes: suppression of IL 2 production by anti-p50 monoclonal antibodies.
Tadmori W; Reed JC; Nowell PC; Kamoun M
J Immunol; 1985 Mar; 134(3):1709-16. PubMed ID: 2981919
[TBL] [Abstract][Full Text] [Related]
7. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.
Cheever MA; Greenberg PD; Irle C; Thompson JA; Urdal DL; Mochizuki DY; Henney CS; Gillis S
J Immunol; 1984 May; 132(5):2259-65. PubMed ID: 6609193
[TBL] [Abstract][Full Text] [Related]
9. Immunologic effects of interleukin 2 in primary immunodeficiency diseases.
Flomenberg N; Welte K; Mertelsmann R; Kernan N; Ciobanu N; Venuta S; Feldman S; Kruger G; Kirkpatrick D; Dupont B; O'Reilly R
J Immunol; 1983 Jun; 130(6):2644-50. PubMed ID: 6222111
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
11. Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.
Sondel PM; Hank JA; Kohler PC; Chen BP; Minkoff DZ; Molenda JA
J Immunol; 1986 Jul; 137(2):502-11. PubMed ID: 2424971
[TBL] [Abstract][Full Text] [Related]
12. Effect of phorbol myristate acetate (PMA) and ionophore A23187 on interleukin-2 levels and proliferation of activated T lymphocytes from patients with lepromatous leprosy.
Alfaro-Bustamante F; Ramirez-Flores G; Gonzalez-Mendoza A; Islas-Rodriguez A; Fafutis-Morris M
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):73-9. PubMed ID: 9207756
[TBL] [Abstract][Full Text] [Related]
13. Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
Albertini MR; Oettel KR; Weil-Hillman G; Lindstrom MJ; Schell K; Hank JA; Sondel PM
J Biol Response Mod; 1990 Oct; 9(5):456-62. PubMed ID: 2254758
[TBL] [Abstract][Full Text] [Related]
14. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor.
Santoli D; Clark SC; Kreider BL; Maslin PA; Rovera G
J Immunol; 1988 Jul; 141(2):519-26. PubMed ID: 3290340
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 (IL 2) relationships with the cancer-related immunodeficiency: in vitro response to exogenous IL 2 by PHA-activated and non PHA-activated peripheral blood mononuclear cells from cancer patients.
Mantovani G; Coiana A; Massidda A; Proto E; Floris C; Macciò A; Pusceddu G; Del Giacco GS
Diagn Clin Immunol; 1987; 5(2):104-11. PubMed ID: 3497733
[TBL] [Abstract][Full Text] [Related]
17. Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy.
de Jong JL; Farner NL; Javorsky BR; Lindstrom MJ; Hank JA; Sondel PM
Clin Cancer Res; 1998 May; 4(5):1287-96. PubMed ID: 9607589
[TBL] [Abstract][Full Text] [Related]
18. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
19. Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.
Weil-Hillman G; Hank JA; Rosenthal NS; Sondel PM
J Biol Response Mod; 1988 Oct; 7(5):424-37. PubMed ID: 3053997
[TBL] [Abstract][Full Text] [Related]
20. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.
Lotze MT; Custer MC; Sharrow SO; Rubin LA; Nelson DL; Rosenberg SA
Cancer Res; 1987 Apr; 47(8):2188-95. PubMed ID: 3030546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
